As by 2016 we do have now different kind of members. Our membership is based on organizations within the public agencies area, but also from academic area. In addition, personal members can request membership
Our global membership
AETSA, Fundacion Pública Andaluza Progreso Y Salud (ES)
AETSA
AGENAS, Agenzia nazionale per i servizi sanitari regionali (IT)
AGENAS
avalia-t, Agencia Gallega para la Gestión del Conocimiento en Salud, ACIS Unidad de Asesoramiento Científico-técnico (ES)
avalia-t
CONITEC, National Committee for Health Technology Incorporation Esplanada dos Ministérios (BR)
Conitec
HTRG, COAG Health Council
Health Technology Reference Group (AU)
HTRG
IHSP, Italian Horizon Scanning Project
UOC Assitenza Farmaceutica Territoriale (IT)
IHSP
ISCIII, Instituto de Salud Carlos III (ES)
ICSIII
MaHTAs, Ministry of Health Malaysia, Health Technology Assessment Section (MY)
MaHTAs
NECA, Department of Horizon Scanning for Innovative Global Health Technology, National Evidence-based Healthcare Collaborating Agency (KR)
NECA
NIHR IO, National Institute of Health Research
Innovation Observatory (UK)
NIHR IO
OSTEBA, Basque Office for Health Technology Assessment (ES)
OSTEBA
SFOPH, Swiss Federal Office of Public Health, Health and Accident Insurance (CH)
SFOPH
ACE, Agency for care effectiveness (SG)
ACE
CDE, Center for Drug Evaluation (TW)
CDE
AIS, Agence de l’innovation en santé (FR)
AIS
INCa, Institut national du cancer (FR)
INCa
Some of our organizational members
1
Stevens A, Milne R, Lilford R, Gabbay J. How do new technologies get into practice? Keeping pace with
new technologies: systems needed to identify and evaluate them. BMJ 1999 (319): 1291-4 2 http://www.phrma.org/medicines_in_development (last access December 2007) 3
Bertele’ V, Banzi R, Capasso F, Tafuri G, Trotta F, Apolone G, Garattini S. Haematological anticancer drugs
in Europe: any added value at the time of approval? Eur J Clin Pharmacol. 2007;63(7):713-9.
4
Garattini S, Bertelè V. How can we regulate medicines better? BMJ. 2007; 335(7624):803-5.
5
Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol.
2006 Mar;61(3):355-60
6 Banta HD. Introduction to the EUR-ASSESS report. Int J Technol Assess Health Care 1997 (13): 133-143
7 Hailey D, Topfer LA, Willis F. Providing information on emerging health technologies to provincial
decision makers: a pilot project Health Policy 2001 Oct; 58 (1): 15-26
8 Simpson S, Vonderling H, Eskildsen D, Simpson S. Use of the Internet in Scanning the Horizon for New
and Emerging Health Technologies: A Survey of Agencies Involved in Horizon Scanning. J Med Internet Res
2003; 5 (1): 1-10
9 Douw K, Vondeling H. Selection of new health technologies for assessment aimed at informing decision
making: A survey among horizon scanning systems. Int J Technol Assess Health Care 2006; 22 (2): 177-183
10 Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging
technologies: Developing an evaluation framework and an assessment of current systems. Int J Technol
Assess Health Care 2007 (3): 324-330
11 Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging
technologies: Developing an evaluation framework and an assessment of current systems. Int J Technol
Assess Health Care 2007 (3): 324-330
12 Martelli F, La Torre G, Di Ghionno E, Staniscia T, Neroni T, Cicchetti A, Von Bremen K, Ricciardi W.
Health technology assessment agencies: An international overview of organizational aspects. Int J Technol
Assess Health Care 2007; 23 (4): 414-424
13 Battista RN, Expanding the scientific basis of health technology assessment: a research agenda for the next
- decade. Int J Technol Assess Health Care. 2006; 22(3):275-80